SCHEMBL5841992

SCHEMBL5841992

CS(=O)(=O)NCCNC(N)=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4D Q6B0I6 1/20 0.35
POLB P06746 2/20 0.33
MALT1 Q9UDY8 1/20 0.33
PTGES O14684 1/20 0.33
KMT2A Q03164 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
SCN9A Q15858 1/20 0.32
CA2 P00918 2/20 0.32
ALDH1A1 P00352 3/20 0.32
MAPT P10636 1/20 0.32
KDM4E B2RXH2 1/20 0.31
TSHR P16473 1/20 0.31
RECQL P46063 1/20 0.31
ALOX15 P16050 1/20 0.31
EPHX2 P34913 1/20 0.31
CA12 O43570 1/20 0.30
CA14 Q9ULX7 1/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1912202 0.79 MAPK1 (0.48) KDM4DPOLBMALT1PTGESALDH1A1
SCHEMBL145975 0.79 KDM4D (0.39) KDM4DPOLBMALT1PTGESKMT2A
SCHEMBL23011666 0.77 KDM4D (0.35) KDM4DPOLBMALT1PTGESKMT2A
SCHEMBL21766639 0.77 MEN1 (0.56) KDM4DMALT1KMT2AALDH1A1TSHR
SCHEMBL5841987 0.77 KDM4D (0.35) KDM4DPOLBMALT1PTGESKMT2A
SCHEMBL3043384 0.77 POLB (0.44) KDM4DPOLBTDP1CA2ALDH1A1
SCHEMBL175234 0.77 TDP1 (0.46) POLBTDP1CA2ALDH1A1KDM4E
SCHEMBL10244714 0.76 KEAP1 (0.38) KDM4DPOLBMALT1PTGESKMT2A
SCHEMBL2709816 0.74 LOXL2 (0.34) TDP1CA2TSHREPHX2
SCHEMBL3378033 0.74 CA12 (0.45) KDM4DPOLBPTGESKMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100412073-C Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2008-08-20 CN claimed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US claimed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP claimed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US claimed
CN-1665800-A Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2005-09-07 CN claimed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP claimed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US claimed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO claimed
CN-100412073-C Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2008-08-20 CN disclosed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
CN-1665800-A Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions DIMENSIONAL PHARM INC (US) 2005-09-07 CN disclosed
EP-0736798-A1 Silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1996-10-09 EP disclosed
EP-0713131-A2 Silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 1996-05-22 EP disclosed
US-5478704-A Method for forming color images FUJI PHOTO FILM CO., LTD. (JP) 1995-12-26 US disclosed
EP-0670312-A1 Color developing agent, processing composition and color image-forming method Fuji Photo Film Co., Ltd. (JP) 1995-09-06 EP disclosed
US-5278034-A Color development agent FUJI PHOTO FILM CO., LTD. (JP) 1994-01-11 US disclosed
EP-0177940-B1 HYDRAZINE DERIVATIVES AND THEIR USE E.R. Squibb & Sons, Inc. (US) 1992-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R KDM4D 4620/4885POLB 4582/4885MALT1 494/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R KDM4D 4813/4885POLB 4433/4885MALT1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.